Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

Clinical trial NCT05826028 · COMPLETED

Trial details

NCT number: NCT05826028
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Study type: OBSERVATIONAL

Secondary Progressive Multiple Sclerosis

Start date: 2020-07-09
Primary completion: 2022-04-20
Enrollment: 368

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.